Cardiol Therapeutics Inc. (CRDL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cardiol Therapeutics Inc. (CRDL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.25

-0.02 (-1.57%)

At close: Jan 14, 2025, 3:59 PM

1.30

3.59%

After-hours Jan 14, 2025, 04:39 PM EST

undefined% (undefined)

Bid	1.21
Market Cap	102.41M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.37
PE Ratio (ttm)	-3.39
Forward PE	n/a
Analyst	Buy

Ask	1.47
Volume	257,240
Avg. Volume (20D)	376,540
Open	1.26
Previous Close	1.27
Day's Range	1.21 - 1.28
52-Week Range	0.96 - 3.12
Beta	undefined

About CRDL

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respirat...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jan 15, 2019

Employees 22

Stock Exchange NASDAQ

Ticker Symbol CRDL

Website https://www.cardiolrx.com

Analyst Forecast

According to 3 analyst ratings, the average rating for CRDL stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 617.13% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 months ago · Source

-6.63%

Cardiol Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

3 months ago · Source

+3.7%

Cardiol Therapeutics shares are trading lower after the company announced a preliminary prospectus for a proposed public offering of common stock, size or amount not disclosed.

News

1 month ago · marketbeat.com

3 Penny Stocks Ready to Break Out in 2025

Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those exp...

1 month ago · proactiveinvestors.com

Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced encouraging results from its Phase II MAvERIC-Pilot study, showcasing the sustained efficacy of its anti-inflammatory therapy, CardiolRx, in trea...

1 month ago · newsfilecorp.com

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week study Episodes of pericarditis per year substantially reduced MAvERIC-Pilot results support ad...

2 months ago · prismmediawire.com

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Company advancing late-stage clinical programs with novel therapies that target underserved heart diseases NEW YORK, November 13, 2024 – PRISM MediaWire – PRISM MarketView, a leading provider of marke...

2 months ago · newsfilecorp.com

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned P...